NeuromarkR™ EEG-Based Assessment Platform
Patented technology designed to provide clinicians and patients with investigational assessment / clinical decision support tools to objectively measure environmentally triggered craving at the point of care.
Why NeuromarkR™?
Based on published research with comparable neurofeedback technologies:
Decrease recurrent drug use by over 25%
Comparable neurofeedback technologies have been associated with decreased recurrent drug use in published studies, suggesting potential benefits under investigation.
Improve treatment retention by over 30%
Comparable neurofeedback technologies have been associated with improved treatment retention rates in published studies, informing our research approach.
200%-300% improved measurement reliability
ERP-based metrics demonstrate superior stability compared to self-report measures, providing a more reliable research tool.
Designed to support cost-effective treatment
Improved trigger awareness and management is hypothesized to potentially reduce treatment costs by supporting more targeted interventions.
Why Address Environmental Triggers?
Environmental triggers jeopardize recovery for the vast majority of people with Substance Use Disorder (SUD), leading to distress, environmentally triggered craving, and recurrent substance use even years after initial treatment.
Improving Outcomes through Awareness
Understanding environmental triggers can improve abstinence rates by 30 to 70%. But, many people are unaware of their triggers, making this awareness challenging to achieve.
Innovative Trigger Management
Noninvasive sensors can measure brain and body responses to environmental triggers, providing valuable insights even if the patient or clinician is unaware. Neurotype Inc. is adapting this science for clinical use to enhance trigger awareness and treatment outcomes.
Objective Measurement
NeuromarkR™ uses noninvasive EEG sensors to measure EEG-derived Event-Related Potentials (ERPs), specifically Visual Evoked Potentials (VEPs), in a 6-minute scan, quantifying the brain’s response to environmental triggers. This tracks changes over time, providing objective data before, during, and after therapy.
Treatment Companion
NeuromarkR™ generates standardized assessment / clinical decision support reports for clinicians, intended to inform therapy evaluation and treatment planning.
Targeted Therapies
We are developing ERP-based closed-loop neurofeedback interventions designed to target environmentally triggered craving, intended to complement psychological, pharmacological, and neuromodulation therapies.
Transparent and Evidence-Based
NeuromarkR™ allows data export for further analysis, supporting transparent, evidence-based care and informed treatment decisions.
Why Neurotype Inc.?
Our PhD-level team has over 30 years of research experience with NeuromarkR™ technologies, dedicated to developing and providing advanced tools for managing environmentally triggered craving and addiction triggers.
Published Science
Learn more about the peer-reviewed research underlying our technology.
